Libang Pharmaceutical was selected as the TOP100 Chinese Chemical Pharmaceutical Enterprises in 2018

On July 15, the "2019 National Pharmacy Week and China Pharmaceutical Innovation and Development Conference" kicked off in Jinan. With the theme of "Value Reconstruction—Searching for Growth, Expanding Boundaries, and Exploring the Future", the conference presented participants with a profound perspective on industry value reconstruction, and worked together to seek industrial value growth points, broaden the boundaries of industrial value, and explore the future development of the industry .

At the meeting, the 2018 China Pharmaceutical Industry Top 100 series list was grandly announced. A total of 5 sub-lists, namely: "China's top 100 chemical pharmaceutical companies list", "China's top 100 traditional Chinese medicine companies list", "China's CRO (including CDMO) company TOP20 list", "China's medical Enterprise TOP20 List", "China Biopharmaceutical (including blood products, vaccines, insulin, etc.) Enterprise TOP20 List".

Xi'an Libang Pharmaceutical Co., Ltd. was successfully selected into the "2018 China Pharmaceutical Industry Top 100 Series List" sub-list "2018 China Chemical Pharmaceutical Enterprise TOP100 List" by virtue of its solid R&D and production strength and stable marketing capabilities, ranking first 66. Fu Jingguo, vice president of Libang Medical Industry Group, attended the meeting and received the award.

Don't forget the original intention, forge ahead. The company will always adhere to the innovative development strategy, increase investment in scientific and technological research and development, accelerate industrial structure adjustment, accelerate product optimization and upgrading, and strive to create more high-quality products, adding new momentum to the healthy development of my country's pharmaceutical industry.

Selection basis:

This series of lists is organized by the Expert Committee of China’s Top 100 Pharmaceutical Industry Rankings organized by Minet Research Institute, relying on the database of the three major terminals and six major market terminal patterns developed and operated by Minet in China for many years, aiming at pharmaceutical industry enterprises, from two important dimensions (innovation driving force and professional promotion ability) for selection.

Background introduction:

The Southern Institute of Medical Economics of the State Drug Administration (hereinafter referred to as "Nanfang Institute") is an institution directly under the State Drug Administration. An institution for research and publication in the medical specialty media.

Minet.com, formerly known as China Medicine Economic Information Network, was founded in September 1997 and is sponsored by the Southern Medicine Economic Research Institute of the State Food and Drug Administration. It is a comprehensive professional information service platform integrating medical and health industry research, hospital market research, and Internet online medical and health information services. It has a wide range of influence in China's medical and health industry.